A new prospective against HIV infection: induction of murin CCR5-downregulating antibodies.

Claudia Barassi(Vita-Salute San Raffaele University), Lucia Lopalco(Vita-Salute San Raffaele University), Renato Longhi(Institute of Chemistry of Molecular Recognition), Adriano Lazzarin(Vita-Salute San Raffaele University), C. Marenzi(Institute of Chemistry of Molecular Recognition), Claudia Pastori(Vita-Salute San Raffaele University)
PubMed
April 1, 2004
Cited by 3

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Control of HIV despite the Discontinuation of Antiretroviral Therapy
|New England Journal of Medicine|1999|328
Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges
|Immunity|2011|285